Arbutus Biopharma Corp
ABUSArbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TKM-080301 | Phase 2 | Cancer | - | - |
ARB-001467 | Phase 2 | Hepatitis B, Chronic | - | - |
AB-729 | Phase 2 | Chronic Hepatitis b | - | - |
Cancer
1 drug in this indication
Chronic Hepatitis b
1 drug in this indication
Hepatitis B, Chronic
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Arbutus Biopharma Corp's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Arbutus Biopharma Corp's (ABUS) pipeline across Phase 2. Its lead program is TKM-080301 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Arbutus Biopharma Corp's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Arbutus Biopharma Corp (ABUS) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ABUS biotech catalysts?→
Add ABUS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Arbutus Biopharma Corp's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.